EA200401010A1 - Порошковое средство для ингаляции, содержащее cgrp-антагонист bibn4096, и способ его получения - Google Patents

Порошковое средство для ингаляции, содержащее cgrp-антагонист bibn4096, и способ его получения

Info

Publication number
EA200401010A1
EA200401010A1 EA200401010A EA200401010A EA200401010A1 EA 200401010 A1 EA200401010 A1 EA 200401010A1 EA 200401010 A EA200401010 A EA 200401010A EA 200401010 A EA200401010 A EA 200401010A EA 200401010 A1 EA200401010 A1 EA 200401010A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cgrp
obtaining
inhalation
powder
bibn4096
Prior art date
Application number
EA200401010A
Other languages
English (en)
Inventor
Михаэль Трунк
Клаудиус Вайлер
Original Assignee
Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг filed Critical Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Publication of EA200401010A1 publication Critical patent/EA200401010A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

В заявке описано порошковое средство для ингаляции, предназначенное для лечения мигрени и содержащее в качестве действующего вещества CGRP-антагонист, представляющий собой основание 1-[N-[3,5-дибром-N-[[4-(3,4-дигидро-2(1H)-оксохиназолин-3-ил)-1-пиперидинил]карбонил]-D-тирозил]-L-лизил]-4-(4-пиридинил)пиперазин [BIBN4096] формулы (I), в виде сферически наноструктурированных частиц, а также описан способ получения такого порошкового средства для ингаляции.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200401010A 2002-02-20 2003-02-17 Порошковое средство для ингаляции, содержащее cgrp-антагонист bibn4096, и способ его получения EA200401010A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10207026A DE10207026A1 (de) 2002-02-20 2002-02-20 Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
PCT/EP2003/001563 WO2003070215A1 (de) 2002-02-20 2003-02-17 Pulverinhalativum, enthaltend den cgrp-antagonisten bibn4096 und verfahren zu dessen herstellung

Publications (1)

Publication Number Publication Date
EA200401010A1 true EA200401010A1 (ru) 2005-02-24

Family

ID=27635158

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401010A EA200401010A1 (ru) 2002-02-20 2003-02-17 Порошковое средство для ингаляции, содержащее cgrp-антагонист bibn4096, и способ его получения

Country Status (22)

Country Link
EP (1) EP1478338B1 (ru)
JP (1) JP4085063B2 (ru)
KR (1) KR20040089646A (ru)
CN (1) CN1638728A (ru)
AR (1) AR038572A1 (ru)
AT (1) ATE299016T1 (ru)
AU (1) AU2003208862A1 (ru)
BR (1) BR0307821A (ru)
CA (1) CA2476621A1 (ru)
DE (2) DE10207026A1 (ru)
EA (1) EA200401010A1 (ru)
EC (1) ECSP045241A (ru)
ES (1) ES2244922T3 (ru)
HR (1) HRP20040747A2 (ru)
IL (1) IL163559A0 (ru)
MX (1) MXPA04008183A (ru)
NO (1) NO20043865L (ru)
PE (1) PE20030832A1 (ru)
PL (1) PL371315A1 (ru)
TW (1) TW200304376A (ru)
UY (1) UY27674A1 (ru)
WO (1) WO2003070215A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10338402A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
DK3010891T3 (da) * 2013-06-19 2019-06-24 Aicuris Anti Infective Cures Gmbh Amorf letermovir og faste farmaceutiske formuleringer deraf til oral indgivelse

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242211A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
DE19937304C2 (de) * 1999-08-10 2003-08-21 Boehringer Ingelheim Pharma Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
ES2343124T3 (es) * 1999-10-29 2010-07-23 Novartis Ag Composiciones de polvo seco con dispersabilidad mejorada.
DE10139410A1 (de) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne

Also Published As

Publication number Publication date
ATE299016T1 (de) 2005-07-15
WO2003070215A1 (de) 2003-08-28
HRP20040747A2 (en) 2005-02-28
PL371315A1 (en) 2005-06-13
IL163559A0 (en) 2005-12-18
ECSP045241A (es) 2004-09-28
EP1478338A1 (de) 2004-11-24
DE10207026A1 (de) 2003-08-28
AR038572A1 (es) 2005-01-19
KR20040089646A (ko) 2004-10-21
TW200304376A (en) 2003-10-01
AU2003208862A1 (en) 2003-09-09
UY27674A1 (es) 2003-09-30
EP1478338B1 (de) 2005-07-06
NO20043865L (no) 2004-09-15
CN1638728A (zh) 2005-07-13
ES2244922T3 (es) 2005-12-16
MXPA04008183A (es) 2004-11-26
BR0307821A (pt) 2004-12-14
JP2005529849A (ja) 2005-10-06
DE50300736D1 (de) 2005-08-11
JP4085063B2 (ja) 2008-04-30
CA2476621A1 (en) 2003-08-28
PE20030832A1 (es) 2003-11-20

Similar Documents

Publication Publication Date Title
PE20040647A1 (es) Inhibidores de cinasas de tirosina
EA200400674A1 (ru) Соли e-2-метокси-n-(3-(4-(3-метилпиридин-3-илокси)фениламино)хиназолин-6-ил)аллил)ацетамида, их получение и их применение против рака
WO2005018603A3 (de) Sprühgetrocknetes, amorphes bibn 4096, verfahren zu dessen herstellung sowie dessen verwendung als inhalativum
RU2489148C2 (ru) Ингибитор активации stat3/5
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
ATE265432T1 (de) 3-amino-5-carboxy-substituierte piperidine und 3- amino-4-carboxy-substituierte pyrrolidine als tachykinin-antagonisten
EA200300919A1 (ru) N-замещенные неарильные гетероциклические антагонисты nmda/nr2b
EA200401191A1 (ru) 4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы
TR200401874T2 (tr) Tert-butil(E)- (6-[2-[4-(4-Fluorofenil)-6-izopropil-2-[metil (metilsülfonil)amino]-pirimidin-5-il]vinil (4R,6S)-2, 2-Dimetil[1,3]Dioksan-4-il)asetatın üretimi için işlem.
EA200500596A1 (ru) Новые амидные соединения, обладающие антагонистическим в отношении mch действием, и содержащие эти соединения лекарственные средства
MXPA06000716A (es) Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1.
NO20055256D0 (no) 4-(4-heterosyklylalkoksy)fenyl)-1-(heterosyklyl-karbonyl)piperidinderivater og beslektede forbindelser som histamin H3-antagonister for behandling av neurologiske sykdommer som Alzheimers
EA200301100A1 (ru) Новые фталазиноны
DE59914814D1 (de) Heterozyklische substituierte amide, deren herstellung und anwendung
RS51923B (en) SO 4 [[4 - [[4- (2-CYANOETHENYL) -2,6-DIMETHYLPHENYL] AMINO] -2-PYRIMIDINYL] AMINO] BENZONITRILA
EA200401584A1 (ru) Способ содействия прекращению курения
ATE481103T1 (de) Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten
EA200401010A1 (ru) Порошковое средство для ингаляции, содержащее cgrp-антагонист bibn4096, и способ его получения
AR038571A1 (es) Procedimiento para la preparacion de un producto de inhalacion en polvo que contiene una sal del antagonista de cgrp, bibn4096
NO962855D0 (no) Nye piperidin-derivater med PAF-antagonist-aktivitet
PE20050897A1 (es) Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
ATE403426T1 (de) Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen
PE20090629A1 (es) Pirazinas y piperidinas piperazinil sustituidas como antagonistas del receptor 5-ht7
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
NO20052803L (no) Komplekser av e-2-metoksy-n-(3-{4-(3-metyl-pyridin-3-yloksy)-fenylam ino)-kinazolin-6-yl}-allyl)acetamid, deres fremstillingsmate og bruk